Biosimilars Resources
The Biosimilars Generation website provides you with links to information about biosimilar regulations and policies in Canada.

Regulators
Health Canada and other Canadian government regulators provide guidance on the safety, efficacy and quality of biologic (original-brand and biosimilar) medicines.
Canadian Agency for Drugs and Technologies in Health (CADTH)
Biosimilar Drugs: Your Questions Answered CADTH Backgrounder on Biosimilars for Health Care Providers
Canadian Institute for Health Information
Prescribed Drug Spending in Canada, 2020: A Focus on Public Drug Programs. Ottawa, ON: CIHI; 2020.
Patented Medicines Prices Review Board
Potential Savings from Biosimilars in Canada
Pan-Canadian Pharmaceutical Alliance
Pan-Canadian Oncology Biosimilars Initiative
Pan-Canadian Oncology Biosimilars Initiative Action Plan
Pan-Canadian Oncology Biosimilars Summit Proceedings Report

Biosimilars Reimbursement Access info
Public payers are adopting biosimilar policies that affect Canadians living with many disabling and life-threatening chronic diseases, such as inflammatory arthritis, certain types of cancer, diabetes, inflammatory bowel disease, Crohn’s disease and psoriasis.
Find more information about biosimilars and their listings on public drug plans.
For up-to-date information about biosimilars transition policy for each public formulary, please visit the websites below:
British Columbia
Biosimilars Initiative for Patients
BC PharmaCare
Alberta
Alberta Biosimilars Initiative
Alberta Health Care Insurance Plan Bulletin
Alberta Health Interactive Drug Benefit List Page
Saskatchewan
eHealth Saskatchewan
Saskatchewan Formulary
Manitoba
Notice – Tiered Biologics Reimbursement Policy
Provincial Drug Formulary
Ontario
Ontario Formulary
Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs
Quebec
Quebec Health
Quebec Prescription Drug Insurance
List of Medications
Nova Scotia
Nova Scotia Health Authority
Nova Scotia Formulary
New Brunswick
New Brunswick Biosimilars Initiative
New Brunswick Biosimilars Initiative – Information for Patients
Newfoundland and Labrador
Newfoundland and Labrador Department of Health and Community Services
Newfoundland and Labrador Formulary
Prince Edward Island
Yukon
Yukon Health and Social Services
Yukon Formulary
Non-insured Health Benefits (NIHB)
Indigenous Health
Non-Insured Health Benefits Program Updates

Patient groups & organizations
Patient organizations are a good source of support and “easy-to-read” information about medicines, including biologics (original-brand and biosimilars).

Biologic (original-brand and biosimilar) manufacturer associations
Biologic (original-brand and biosimilar) manufacturer associations provide information on biologic medicines.